Kornimate/medical-research-clean huggingface dataset:
extension for community healthcare outcomes (echo) autism diagnostic study in primary care setting

Conditions: Children18-72 Months With a Suspicion Autistic Disorder

Summary: this is a collaborative study that will provide a comprehensive source of observational data that can be used to obtain real world evidence of asd. the study will contain demographic and observational clinical data for eligible participants. all decisions regarding patient care will be determined by the echo autism clinician (eac). all clinical outcomes will be assessed by the eac as would occur in routine clinical practice.

the study will be conducted by the university of missouri echo autism communities research team (rt). research participants recruited by the rt will include: 1) university of missouri echo autism community trained clinicians (eacs) in both rural and suburban areas across the united states; 2)caregivers/patients with a suspicion of autism. caregivers/patients with a suspicion of autism and eacs will complete the informed consent process prior to entering the study. once enrolled, eacs will provide routine clinical care and conduct best-practice echo autism diagnostic evaluations with the addition of canvas dx to patients who have a suspicion of autism spectrum disorder. canvas dx will be prescribed; the caregiver will download and access the diagnostic app with a code. the caregiver will then complete the following activities: * complete caregiver questionnaire in the mobile app * upload two 90 sec to 5-minute videos of the participant through the mobile app

Eligibility criteria:
inclusion criteria: 1. english is spoken proficiently by the participating patient/family, in the opinion of the eac. 2. meets labeling of device 3. parent, guardian, or legally authorized representative (lar) must be able to read, understand, and sign and date the informed consent form (icf) 4. sex assigned at birth (female or male or non-binary) 5. female or male, \> 18 to \< 72 months of age 6. caregiver, hcp or community-based professional concern for developmental delay or autism 7. parent/guardian/lar must have smartphone utilizing the most recent and previous version of ios and android operating systems (ios 13 or 14; android 10 or 11, excluding android go) 8. participants must be willing to be videotaped as part of the device input exclusion criteria: 1. participants with a prior diagnosis of autism spectrum disorder (asd) rendered by a healthcare professional 2. participants with any other medical, behavioral, or developmental condition that in the opinion of the echo autism clinician may confound study data/assessments 3. participants whose age on the date of enrollment is outside the target age range 4. participants or caregivers who have, to the best of their knowledge, been previously enrolled in any cognoa clinical study or survey

Keywords: autism
dry needling and therapeutic exercise on sleep in individuals with chronic neck pain and sleep disturbance

Conditions: Neck Pain; Sleep Disturbance

Summary: feasibility study investigating the effects of dry needling on individuals with chronic neck pain and sleep disturbance.

the purpose of this pilot study is to determine the feasibility of a large randomized clinical trial (rct) which aims to investigate the effects of dry needling (dn) in addition to therapeutic exercise (te) on sleep duration and quality in patients with chronic neck pain (cnp) and sleep disturbance (sd). specifically, the objective is to explore feasibility of a study protocol and examine the preliminary data of a small sample size for the effectiveness of dn and te for individuals with cnp and sd to determine effect size of the intervention.

Eligibility criteria:
inclusion criteria: * neck pain lasting greater than 3 months 28,29 * age: 18-75 years * presence of sleep disturbance - to be defined as a score ≥ 8 on the insomnia severity index * ability to understand study procedures and to comply with them for the entire length of the study exclusion criteria: * previous surgery to the neck or thoracic spine * central nervous system disorders * systemic joint disease (e.g. rheumatoid arthritis) * infection * cancer * raynaud's disease * pregnancy * immunocompromised disease (e.g., diabetes mellitus, hiv, aids, lupus) * insufficient english-language skills to complete all questionnaires. * contraindications to dry needling: * presence of needle phobia * history of abnormal reaction to needling or injection * history of bleeding disorder (e.g., current anticoagulant therapy or known thrombocytopenia)

Keywords: needling sleep disturbance chronic pain neck pain actigraphy physical therapy feasibility
genomic landscape of intramedullary astrocytoma

Conditions: Spinal Cord Astrocytoma

Summary: intramedullary astrocytoma is a rare and devastating spinal cord glioma. while the management of intracranial astrocytoma includes gross total resection, radiotherapy and chemotherapy, spinal cord astrocytoma is very difficult to be totally removed due to its infiltrative nature and unclear plane of dissection; moreover, the use radiotherapy and chemotherapy for spinal cord astrocytoma is controversial. therefore, the treatment for spinal cord astrocytoma is very limited as compared to its intracranial counterpart. inadequate understanding of spinal cord astrocytoma mainly contribute to limited treatment, while the molecular profiling of intracranial astrocytoma is relatively well understood. hence, we performed whole-exome sequencing of intramedullary astrocytoma aiming to identify the pathophysiological mechanisms underlying spinal cord astrocytoma

intramedullary tumor only account for 2-4% of central nervous tumor. of which, ependymoma and astrocytoma represent the most common intramedullary tumor. although intramedullary astrocytoma is rare, it can cause significant mortality and morbidity. different from its intracranial counterpart which can receive gross total resection and standard adjuvant treatment, intramedullary astrocytoma always cannot be removed completed due to its infiltrative nature and, additionally, radiotherapy and chemotherapy is controversial. therefore, the treatment for this tumor is very limited. while the genetic profiling of intracranial astrocytoma is relatively well understood and standard treatment strategy has been developed, genetic alteration of intramedullary astrocytoma is less well understood. identification of the molecular profiling can lead to well understanding of the pathophysiological mechanisms underlying intramedullary astrocytoma and more effective therapeutic strategy in future. hence, we performed this study aiming to investigate the genetic profiling of intramedullary. all patients with intramedullary astrocytoma underwent surgery in our institution will be enrolled. tumor tissue and matching blood will be obtained after the surgery. whole-exome sequencing was performed on dna extracted from these specimens. moreover, demographic information, progress-free survival and overall survival will be evaluated in 3 year of follow-up after the initial diagnosis.

Eligibility criteria:
inclusion criteria: * patients that histologically diagnosed as primary spinal cord astrocytoma exclusion criteria: * patients with spinal cord tumors rather than astrocytoma * metastatic astrocytoma * tumor sample can not be obtained

Keywords: spinal cord astrocytoma; whole-exome sequencing;
study of esg406 in adults with solid tumors

Conditions: Locally Advanced/Metastatic Solid Tumors

Summary: this study is an open-label, dose-escalation and cohort expansion phase i study, aiming to evaluate the safety, tolerability, pk characteristics and preliminary efficacy of esg406, and determine the mtd, rp2d and administration regimens of esg406. the study includes the dose escalation study in phase ia and the cohort expansion study in phase ib.


Eligibility criteria:
key inclusion criteria: * males and females aged 18 to 80 years. * histologically or cytologically confirmed advanced or metastatic solid tumor(s) for which no effective standard therapy is available or tolerable. * at least one measurable lesion per recist v1.1. * eastern cooperative oncology group (ecog) performance status of 0 or 1. * life expectancy ≥12 weeks. * adequate organ and bone marrow function. * fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 180 days after last investigational product administration. women of childbearing potential include pre-menopausal women and women within the first 2 years of the onset of menopause. key exclusion criteria: * use of any cancer therapy (chemotherapy or other systemic anti-cancer therapies, immunotherapy) within 4 weeks before the first investigational product administration. * toxicities from prior anti-tumor therapy not recovering to ≤ grade 1. * had major surgery within 4 weeks before dosing, or will not have fully recovered from surgery; or has surgery planned during the time the subject is expected to participate in the study or within 4 weeks after the last dose of study drug administration. * use of any investigational anti-cancer drug within 4 weeks or 5 half-lives before the first investigational product administration. * a history of thromboembolic or cerebrovascular events within 6 months prior to the first dose of the investigational drug. * history of (noninfectious) interstitial pneumonia (ild)/noninfectious pneumonitis requiring steroid therapy and current ild/noninfectious pneumonitis, or suspected ild/noninfectious pneumonitis at screening. * subjects with symptomatic or untreated cns metastases, or those requiring ongoing treatment for cns metastases. * patients with primary cns malignancy, or patients with other malignancies within 3 years prior to the first dose. * patients with uncontrollable systemic diseases. * subjects with clinically significant cardiovascular disease. * human immunodeficiency virus (hiv) infection. * active hepatitis b or hepatitis c. * have an allergic constitution, or to be allergic to any investigational drug or excipient ingredient. * pregnant or lactating women.
role of clinical pulmonary infection score and sonopulmonary infection score in diagnosis and predicting outcome of vap in rucu

Conditions: Patients with VAP in RICU Patients

Summary: -pneumonia is a bacterial, viral or fungal infection of the lungs, which causes the alveoli of the lungs to fill up with microorganisms, fluid and inflammatory cells, preventing the lungs from functioning effectively the classification scheme for pneumonia in uk nhs hospitals is based on the setting in which the infection was mostly likely acquired: community-acquired pneumonia (cap), when a patient is in the hospital \ 48h before the pneumonia develops, but is not associated with mechanical ventilation; and ventilator-associated pneumonia (vap), when a patient is mechanically ventilated and intubated for \>48h before the pneumonia develops the causative pathogens in each scenario are different, and treatment strategies vary as a consequence.

-pneumonia is a bacterial, viral or fungal infection of the lungs, which causes the alveoli of the lungs to fill up with microorganisms, fluid and inflammatory cells, preventing the lungs from functioning effectively the classification scheme for pneumonia in uk nhs hospitals is based on the setting in which the infection was mostly likely acquired: community-acquired pneumonia (cap), when a patient is in the hospital \ 48h before the pneumonia develops, but is not associated with mechanical ventilation; and ventilator-associated pneumonia (vap), when a patient is mechanically ventilated and intubated for \>48h before the pneumonia develops the causative pathogens in each scenario are different, and treatment strategies vary as a consequence.

Eligibility criteria:
inclusion criteria: * patient 18 yrs or more mechanically ventilated patients after 48 hrs after admission of icu exclusion criteria: * patient less than 18 yrs patients diagnosed as pneumonia
safety and efficacy of mts versus concerta in pediatric patients (aged 6-12 years) with adhd

Conditions: Attention Deficit Hyperactivity Disorder

Summary: study designed to evaluate the safety and efficacy of mts compared to placebo with reference to concerta® in pediatric subjects diagnosed with adhd.

this is a phase iii, randomized, double-blind, multi-center, parallel-group, placebo-controlled, dose optimization study designed to evaluate the safety and efficacy of mts (12.5, 18.75, 25, and 37.5 cm2) compared to placebo with reference to concerta® in pediatric subjects diagnosed with attention deficit hyperactivity disorder (adhd).

Eligibility criteria:
inclusion criteria: * male or female aged 6-12 years * females of child-bearing potential (focp) must have a negative serum beta human chorionic gonadotropin (hcg) pregnancy test at screening and a negative urine pregnancy test at baseline. * a primary diagnosis of adhd based on a detailed psychiatric evaluation * a total score of =\>26 on the adhd-rs-iv at the baseline visit * a minimum level of intellectual functioning, as determined by an iq (based on kbit) score of 80 or above * no comorbid illness that could affect safety or tolerability or in any way interfere with the subject's participation in the study. exclusion criteria: * a current, controlled (requiring a restricted medication) or uncontrolled, comorbid psychiatric diagnosis (except odd) with significant symptoms such as post traumatic stress disorder (ptsd), psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder * a known non-responder to psychostimulant treatment * overweight (body mass index (bmi)-for-age \>90th percentile) * a history of seizures during the last 2 years (exclusive of infantile febrile seizures), a tic disorder, a current diagnosis and/or family history of tourette's disorder. * conduct disorder. * subject has taken an investigational drug within 30 days prior to screening.

Keywords: attention deficit hyperactivity disorder (adhd)
olfactory function and postoperative cognitive dysfunction

Conditions: Postoperative Cognitive Dysfunction

Summary: to study the correlation of pocd with olfactory function. to explore whether enhanced olfactory stimuli can reduce the risk of pocd as a preventive strategy.

postoperative cognitive dysfunction (pocd), the most common complications of geriatric surgical patients, could contribute to long-term social dysfunction, high mortality and increased medical cost. previous studies have suggested that impaired olfaction was related to postoperative delirium (nadya m. dhanani et al, j clin anesth 2012; charles h. brown iv et al, j am geriatr so 2015; min seung kim et al, j neural transm 2016). however, there is still no efficient treatment for pocd, and it also remains largely unknown whether enhanced olfactory stimuli can be used as an inventive strategy to reduce the risk of pocd.

Eligibility criteria:
inclusion criteria: 1. keen surgery under general anesthesia; 2. age is greater than or equal to 65 years old; 3. han nationality, mother tongue is chinese; 4. the mmse score: illiteracy is greater than or equal to 17 points, primary school is greater than or equal to 20 points, higher secondary school is more than 24 points; 5. being able to complete the assessments without serious visual or hearing difficulty; 6. without serious heart, brain, liver, kidney, lung and other organs; 7. without serious neurological and psychiatric disorders, such as alzheimer's disease, parkinson's syndrome, multiple sclerosis, schizophrenia, depression, etc.; 8. the asa class i or ii; 9. the people signed informed consent. exclusion criteria: 1. had severe head and face disease, trauma history or history of surgery; 2. had a history of influenza in 3 weeks; 3. the serious body disease and tobacco, wine and other substance abuse history; 4. the presence of malignant tumor with shorter survival disease.
the role of rheumatological evaluation in the management of patients with interstitial lung disease

Conditions: Interstitial Lung Disease; Idiopathic Pulmonary Fibrosis; Connective Tissue Disease

Summary: we hypothesized that the multi-disciplinary assessment of interstitial lung disease patients would lead to a more accurate diagnosis and consequently alterations in treatment regimens that may lead to improved outcomes.


Eligibility criteria:
inclusion criteria: * age above 18 years old * ild according to ats/ers guidelines * signed inform consent exclusion criteria: * previous lung surgery * other significant systemic disease

Keywords: interstitial lung disease idiopathic pulmonary fibrosis connective tissue disease
radiation exposure reduction in supraventricular tachycardia ablation

Conditions: Supraventricular Tachycardias

Summary: radiofrequency catheter ablation (rfca) is the mainstay of therapy for supraventricular tachyarrhythmias, providing cure in a high percentage of cases. conventional ablation techniques require the use of fluoroscopy to place and navigate catheters in the heart, thus exposing patients to ionizing radiations with an additional risk of cancer. the feasibility and safety of a non-fluoroscopic rfca of a wide range of supraventricular arrhythmias using the ensite navx mapping system have been recently reported. the no-party is a multicenter, randomized-controlled trial designed to test the hypothesis that supraventricular arrhythmias rfca through the non-fluoroscopic ensite navx mapping system results in a clinically significant reduction of the exposure to ionizing radiations compared with conventional ablation techniques. no-party trial will determine whether supraventricular tachyarrhythmia rfca through a non-fluoroscopic ensite navx mapping system is a suitable and cost-effective approach to achieve a clinically significant reduction of ionizing radiation exposure for both the patient and the operator.


Eligibility criteria:
inclusion criteria: * male and female patients between 14 and 50 years of age who have received an indication to radiofrequency catheter ablation of supraventricular arrhythmias according to current guidelines. exclusion criteria: * atrial fibrillation or non isthmus-dependent atrial flutter * pregnancy * hematological contraindications to ionizing radiation exposure * presence of complex congenital heart disease, and cardiac surgery within 1 month from enrollment

Keywords: supraventricular arrhythmia catheter ablation
phase i multiple-ascending dose (japan)

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (pk), and pharmacodynamics (pd) following once daily oral doses of 2.5, 10, and 20 mg of dapagliflozin in diabetic japanese subjects administered for 14 days


Eligibility criteria:
inclusion criteria: * japanese male and female subjects * ages 20 to 70 years old * established diagnosis of t2dm * bmi \< 32 kg/m2 * fasting glucose ≤ 240 mg/dl, while on antidiabetic diet alone * hba1c 6.0 - 10.0% exclusion criteria: * symptomatic t2dm defined as polyuria and/or polydipsia within 2 months of enrollment * history of diabetic ketoacidosis or hyperosmolar nonketotic syndrome * history of incontinence or bladder dysfunction including nocturia
demonstration of an electronic clinical decision support module for dengue in burkina faso

Conditions: Dengue

Summary: the integrated management of childhood illness (imci) guideline has been implemented in burkina faso and is used across primary health facilities to assess children under the age of 5 years. a part from a rapid diagnostic test (rdt) for malaria, no other point of care in vitro diagnostic tests are widely used to improve disease diagnosis and inform treatment decisions. dengue fever has been reported in burkina faso since 1925 and the recent epidemics in 2016 and 2017 have prompted the government to validate and deploy a clinical management algorithm for dengue and a case reporting process to support surveillance for a targeted response. the organisation terre des hommes has digitalised imci and implemented the module through its integrated electronic diagnosis approach (ieda) programme across primary health care centers (phcs) in the country with proven impact on clinical care and proven reduction in antibiotic prescriptions. many recognize the need to update the imci guideline with current evidence. however this is challenging and may require large clinical trials. the advantage of electronic clinical decision support systems is plural: they improve quality of care through increased adherence and feedback information to the system; they strengthen surveillance systems by connecting relevant patient related data and provide geo-tagged coordinates for targeted responses; and they can become evidence-adaptive. an electronic module of the burkina faso dengue clinical management guideline accompanied with dengue rapid diagnostic tests has the potential to improve the diagnosis of non-malaria fevers in particular during "dengue seasons" and improve the efficiency of surveillance for this disease. in this study, the investigators aim to assess the usability and the performance of the dengue module for patient management in primary health care facilities.


Eligibility criteria:
inclusion criteria: * older than 6 month * presentation with fever (axillary temperature ≥ 37,5⁰c) or history of fever for 2-7 days without localizing signs of another pathology such as malaria diagnosed by rdt * malaria diagnosis: negative malaria rdt performed at the the study site by a nurse as part of the routine consultation, or a positive malaria rdt with antimalarial treatment failure exclusion criteria: * neonates (0-2 months) and children ≤ 6 month for operational reasons such as difficulties with blood draw * patients with severe disease requiring urgent care

Keywords: non-malarial fevers clinical decision support tools rapid diagnostic test